Back |
home / stock / etnb / etnb message board
Subject | By | Source | When |
---|---|---|---|
Yes you did brotha and man oh man | doogdilinger | investorshub | 10/06/2022 2:50:20 PM |
That's because I changed my sleeping patterns lol. | subslover | investorshub | 10/06/2022 2:40:34 PM |
It's truly AMAZING how friggin' HOT you've been | doogdilinger | investorshub | 10/06/2022 2:32:34 PM |
BEAUTIFUL DAY!!!!!! Keep the rally going MR McDoog | subslover | investorshub | 10/05/2022 12:40:30 AM |
Thinking we will have a good week here | subslover | investorshub | 10/03/2022 1:04:33 AM |
Still looking sweet. Have a nice weekend | subslover | investorshub | 09/17/2022 1:46:42 AM |
40% in da bag today! Have a good night | subslover | investorshub | 09/13/2022 11:47:15 PM |
Howling | BigBadWolf | investorshub | 09/13/2022 7:00:14 PM |
89bio Inc yep on fire & centered in | BigBadWolf | investorshub | 09/13/2022 6:57:54 PM |
The early bird catches the worm Me Ole | subslover | investorshub | 09/13/2022 2:13:43 PM |
You're beyond blazin' HOT subs buddy>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ | doogdilinger | investorshub | 09/13/2022 2:09:13 PM |
$ETND on Fire! | subslover | investorshub | 09/13/2022 12:17:54 PM |
Setting up nicely | doczaius | investorshub | 07/13/2020 8:49:42 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...